MBP-426, which has recently entered a clinical II study, is a Tf-conjugated N-glutaryl phosphatidylethanolamine (NGPE)-liposome developed to improve the safety and efficacy of delivery of oxaliplatin into cancer cells by targeting TFR [155]. The gene discussed is TFRC; the disease is cancer.